文献速递免疫规划传染病防控与疫情报告

灭活柯萨奇病毒A6、A10和A16疫苗对手足口病的免疫原性与保护效果

The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
PubMed 文献 · Vaccine · 2018-05-05

本研究评估了经福尔马林或β-丙内酯(BPL)在不同条件下灭活的柯萨奇病毒A6、A10和A16(CA6、CA10、CA16)作为多价疫苗候选株的免疫原性。CA6在两种灭活方法下诱导相似的免疫应答,而CA10和CA16经BPL灭活后的免疫效果优于福尔马林灭活。BPL灭活(BI)单价疫苗组对异源毒株无足够的交叉反应性或交叉保护性;BI三价疫苗组诱导了足够的中和抗体和细胞介导的免疫应答。

要点

  • CA6经福尔马林或BPL灭活诱导相似的免疫应答。
  • CA10和CA16经BPL灭活后的免疫效果优于福尔马林灭活。
  • BI三价疫苗组诱导了足够的中和抗体和细胞介导的免疫应答。

核心结论

  • BI-CA6、CA10和CA16是潜在的多价疫苗候选株,且控制手足口病需要多价疫苗。
  • 柯萨奇病毒多价疫苗可能有助于开发有效的手足口病疫苗。

研究设计与样本

  • 本研究将CA6、CA10和CA16在不同条件下经福尔马林或β-丙内酯(BPL)灭活,评估其作为多价疫苗候选株的免疫原性。

主要发现

  • CA6在两种灭活方法下诱导相似的免疫应答。
  • CA10和CA16经BPL灭活后的免疫效果优于福尔马林灭活。
  • BPL灭活(BI)单价疫苗组对异源毒株无足够的交叉反应性或交叉保护性。
  • BI三价疫苗组诱导了足够的中和抗体和细胞介导的免疫应答。

关键数值与推荐

  • CA6在福尔马林灭活与BPL灭活下诱导相似的免疫应答。
  • CA10和CA16经BPL灭活后的免疫效果优于福尔马林灭活。
  • BI单价疫苗组对异源毒株无足够的交叉反应性或交叉保护性。
  • BI三价疫苗组诱导了足够的中和抗体和细胞介导的免疫应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coxsackievirus belongs to the Enterovirus genus of the Picornaviridae family and is one of the major pathogens associated with human hand, foot, and mouth disease (HFMD). Historically, outbreaks of HFMD have mainly been caused by enterovirus 71 and coxsackievirus A16. Recently, coxsackieviruses A6 and A10 have been associated with increased occurrences of sporadic HFMD cases and outbreak events globally. In this study, the immunogenicity of coxsackieviruses A6, A10, and A16 (CA6, CA10, and CA16), which were inactivated by formalin or β-propiolactone (BPL) under different conditions, was evaluated as multivalent vaccine candidates. CA6 induced similar immune responses with both inactivation methods, and the immune efficacy of CA10 and CA16 was better following inactivation with BPL than with formalin. There was no sufficient cross-reactivity or cross-protectivity against heterologous strains in groups vaccinated with the BPL-inactivated (BI) monovalent vaccine. Sufficient neutralizing antibody and cell-mediated immune responses were induced in the BI-trivalent vaccinated group. These findings suggest that BI-CA6, CA10, and CA16 are potential multivalent vaccine candidates and that a multivalent vaccine is needed to control HFMD. The coxsackievirus multivalent vaccine could be useful for the development of effective HFMD vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lim H, In HJ, Lee JA, et al. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018. PMID: 29739716. doi:10.1016/j.vaccine.2018.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。